Actinium Pharmaceuticals
ATNM
45 hedge funds and large institutions have $3.12M invested in Actinium Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
13% more funds holding
Funds holding: 40 → 45 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.23% less ownership
Funds ownership: 0.52% → 0.29% (-0.23%)
46% less capital invested
Capital invested by funds: $5.8M → $3.12M (-$2.68M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$161K |
| 2 |
Renaissance Technologies
New York
|
+$113K |
| 3 |
VF
Virtu Financial
New York
|
+$70K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.9K |
| 5 |
Jane Street
New York
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$1.38M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.27M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$156K |
| 4 |
OC
Oppenheimer & Co
New York
|
-$53.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$35K |
ATNM Hedge Fund Activity: Q4 2019 in Review
45 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2019, worth a combined $3.12M — down 46% from $5.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATNM positions and 7 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $161K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.38M sold.
- 45 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2019, up from 40 in Q3 2019.
- Funds reported $3.12M of Actinium Pharmaceuticals stock for Q4 2019, down 46% quarter-over-quarter.
- 12 funds opened new Actinium Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +5 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $161K added.
- The largest Actinium Pharmaceuticals seller in Q4 2019 was Sio Capital Management, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2019.